Goldman Sachs
ENFN

Goldman Sachs’s Enfusion, Inc. ENFN Stock Holding History

Goldman Sachs’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-146,016
Closed -$1.63M – 6566
2025
Q1 		$1.63M Sell
146,016
-46,690
-24% -$516K ﹤0.01% 4327
2024
Q4 		$1.98M Buy
192,706
+72,936
+61% +$705K ﹤0.01% 4285
2024
Q3 		$1.14M Buy
119,770
+70,741
+144% +$610K ﹤0.01% 4550
2024
Q2 		$418K Sell
49,029
-5,391
-10% -$49.3K ﹤0.01% 4923
2024
Q1 		$503K Buy
54,420
+205
+0.4% +$1.8K ﹤0.01% 4745
2023
Q4 		$526K Sell
54,215
-87,922
-62% -$821K ﹤0.01% 4719
2023
Q3 		$1.27M Buy
142,137
+73,407
+107% +$697K ﹤0.01% 4100
2023
Q2 		$771K Sell
68,730
-18,482
-21% -$164K ﹤0.01% 4504
2023
Q1 		$916K Buy
87,212
+49,835
+133% +$549K ﹤0.01% 4432
2022
Q4 		$361K Buy
37,377
+10,414
+39% +$117K ﹤0.01% 5051
2022
Q3 		$333K Buy
26,963
+15,589
+137% +$190K ﹤0.01% 5242
2022
Q2 		$116K Sell
11,374
-62,447
-85% -$690K ﹤0.01% 5815
2022
Q1 		$939K Buy
+73,821
New +$1.13M ﹤0.01% 4870

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's ENFN Position: Q2 2025 in Review

Goldman Sachs sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 146,016 shares — an estimated $1.63M sold.

Goldman Sachs first reported a position in ENFN in Q1 2022 and held it in 13 quarters. The position peaked at $1.98M in Q4 2024. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • Goldman Sachs reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 146,016 Enfusion, Inc. shares in Q2 2025, an estimated $1.63M.
  • Goldman Sachs first reported a position in Enfusion, Inc. in Q1 2022 and held it in 13 quarters.
  • Goldman Sachs's Enfusion, Inc. position peaked at $1.98M in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.